Alkermes (ALKS) says top-line results from a phase 2b dose-ranging clinical study of ALKS 37 in...

|About: Alkermes plc (ALKS)|By:, SA News Editor

Alkermes (ALKS) says top-line results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation did not satisfy its pre-specified criteria for advancing into phase 3 clinical trials. Based on the evaluation, Alkermes has decided not to advance ALKS 37 and will consider out-licensing opportunities.